Results 61 to 70 of about 11,404 (192)

Sex‐specific impact of repeated adolescent vapour exposure to JWH‐018 on dopamine response, behaviour and pharmacokinetics across adolescence and adulthood

British Journal of Pharmacology, Volume 183, Issue 7, Page 1517-1538, April 2026.
Abstract Background and Purpose Alarming trends show that vaping e‐cigarettes containing synthetic cannabinoid receptor agonists, such as JWH‐018, is increasing among youth. However, the effects of these trends are unclear in both sexes. We therefore characterized the neuropharmacological effects of adolescent JWH‐018 inhalation in male and female rats.
Nicholas Pintori, Cristina Manis, Enrica Spano, Nicola Simola, Alessandro Ieraci, Pierluigi Caboni, Gaetano Di Chiara, Maria Antonietta De Luca   +7 more
wiley   +1 more source

β-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain

Molecules, 2019
Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs), therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available drugs.
Esraa Aly, Maitham A. Khajah, Willias Masocha   +2 more
doaj   +1 more source

Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol

Arhiv za Higijenu Rada i Toksikologiju, 2020
Cannabis sativa L. contains more than 100 phytocannabinoids that can interact with cannabinoid receptors CB1 and CB2. None of the cannabinoid receptor ligands is entirely CB1- or CB2-specific. The effects of cannabinoids therefore differ not just because
Černe Katarina
doaj   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, Volume 183, Issue 7, Page 1364-1389, April 2026.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Metabolic dysfunction‐associated fatty liver disease (MAFLD), recently redefined from non‐alcoholic fatty liver disease (NAFLD), highlights the central role of metabolic dysfunction in its pathophysiology. The L‐α‐lysophosphatidylinositol/G protein‐coupled receptor 55 (LPI/GPR55) axis, an element of the endocannabinoidome, has emerged as a key
Jerome Lian, Ricky R Lareu, Mohan Patil, Marco Falasca   +3 more
wiley   +1 more source

Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis.

PLoS ONE, 2013
Endocannabinoids and some phytocannabinoids bind to CB1 and CB2 cannabinoid receptors, transient receptor potential vanilloid one (TRPV1) receptor and the orphan G protein receptor fifty-five (GPR55).
Sofia Sisay, Gareth Pryce, Samuel J Jackson, Carolyn Tanner, Ruth A Ross, Gregory J Michael, David L Selwood, Gavin Giovannoni, David Baker   +8 more
doaj   +1 more source

Exploring the Therapeutic Potential of Cannabidiol in Cutaneous Squamous Cell Carcinoma: An Integrated Computational and Experimental Study

International Journal of Quantum Chemistry, Volume 126, Issue 5, March 5, 2026.
Cannabidiol (CBD) exhibits increased reactivity, stronger CB1 receptor binding, and enhanced cytotoxicity against A431 squamous carcinoma cells compared to 5‐fluorouracil (5‐FU). Integrated DFT, molecular docking, and experimental analyses demonstrate CBD's improved stability and binding affinity, highlighting its potential as an alternative ...
Andrea Jess Josiah, Krishna Kuben Govender, Penny Poomani Govender, Werner Cordier, Margo Nell, Suprakas Sinha Ray   +5 more
wiley   +1 more source

Cannabinoid Receptor CB2 Is Involved in Tetrahydrocannabinol-Induced Anti-Inflammation against Lipopolysaccharide in MG-63 Cells

Mediators of Inflammation, 2015
Cannabinoid Δ9-tetrahydrocannabinol (THC) is effective in treating osteoarthritis (OA), and the mechanism, however, is still elusive. Activation of cannabinoid receptor CB2 reduces inflammation; whether the activation CB2 is involved in THC-induced ...
Lei Yang, Fei-Fei Li, Yu-Chen Han, Bin Jia, Yin Ding   +4 more
doaj   +1 more source

METHODS FOR RECOMBINANT EXPRESSION AND FUNCTIONAL CHARACTERIZATION OF HUMAN CANNABINOID RECEPTOR CB2

Computational and Structural Biotechnology Journal, 2013
Cannabinoid receptor CB2 is a seven transmembrane-domain integral membrane protein that belongs to a large superfamily of G protein-coupled receptors (GPCR).
Alexei A. Yeliseev
doaj   +1 more source

Programming Next‐Generation Synthetic Biosensors by Genetic Circuit Design

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Synthetic biology enables genetic circuit‐based biosensing to detect diverse targets, process signals, and transduce them into readable outputs or intracellular regulatory activities. However, field deployment and real‐world application of such synthetic biosensors face considerable challenges in sensitivity, specificity, speed, stability, and ...
Yuanli Gao, Cheng Huang, Jiaxuan Deng, Lei Wang, Baojun Wang   +4 more
wiley   +1 more source